Labelling and 'Dear Doctor' letters: Are they noncommittal?

Drug Safety

Volumn 25, Issue 15, 2002, Pages 1051-1055

  Van Grootheest, A C Kees ^a   Edwards, I Ralph ^b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN;

DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HUMAN; PATIENT COMPLIANCE; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RESPONSIBILITY; REVIEW; RHABDOMYOLYSIS;

DRUG INFORMATION SERVICES; DRUG LABELING; EDUCATION, MEDICAL, CONTINUING; HUMANS; PHARMACEUTICAL PREPARATIONS; PROFESSIONAL AUTONOMY; RISK ASSESSMENT;

EID: 0036913686     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225150-00001     Document Type: Review

References (9)

1. Jones JK, Fife D, Curkendall S, et al. Co-prescribing and co-dispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607-9
2. Weatherby LS, Walker AM, Fife D, et al. Contraindicated medications dispensed with cisapride: Temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10: 211-8
3. Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001; 286: 831-3
4. Jabaay L, Stokx LJ, Bakker DH de. Artrosemiddel in de lift. Med Contact (Bussum) 2001; 56: 1493-6
5. Edwards IR, Wiholm BE, Martinez C. Concepts in risk-benefit assessment: A simple merit analysis of a medicine. Drug Saf 1996; 15 (1): 1-7
6. Food and Drug Modernization Act (FDAMA). Public Law 105-17
7. Raftery J. National Institute for Clinical Excellence (NICE): Faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-3
8. International Conference on Developing Effective Communications in Pharmacovigilance. Effective communications in pharmacovigilance, the Erice report: Report of the Conference on Developing Effective Communications in Pharmacovigilance; 1997 Sep 24-27; Erice, Sicily. WHO Uppsala Monitoring Centre, 1998
9. van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 (3): 205-10